Biosimilar Newsletter Archive

  1. 11.22.17 -- Biosimilar Education Demands Creativity
    11/22/2017
    11/22/17 Biosimilar Development Newsletter
  2. 11.16.17 -- Biosimilar Education: Patient Group Perspectives
    11/16/2017
    11/16/17 Biosimilar Development Newsletter
  3. 11.09.17 -- 3 Big Concerns At DIA Biosimilars 2017
    11/9/2017
    11/09/17 Biosimilar Development Newsletter
  4. 11.02.17 -- Pfizer's Cultural Evolution Into Biosimilar Development
    11/2/2017
    11/02/17 Biosimilar Development Newsletter
  5. 10.26.17 -- Don't Fear Exploration In Biosimilar Development
    10/26/2017
    10/26/17 Biosimilar Development Newsletter
  6. 10.19.17 -- How Can Biosimilars Remain Politically Relevant?
    10/19/2017
    10/19/17 Biosimilar Development Newsletter
  7. 10.12.17 -- New CEO Sizes Up Biosimilar Industry's Future
    10/12/2017
    10/12/17 Biosimilar Development Newsletter
  8. 10.05.17 -- How These Two Mottos Will Impact Biosimilars
    10/5/2017
    10/05/17 Biosimilar Development Newsletter
  9. 10.03.17 -- The Manufacturing Risk Biosimilar Companies Can't Afford To Ignore
    10/3/2017
    10/03/17 Biosimilar Development Newsletter
  10. 09.28.17 -- The State Of Global Biosimilar Risk Management Programs
    9/28/2017
    09/28/17 Biosimilar Development Newsletter